The subgroup analyses showed a trend towards a higher risk of infection in the T/C group when restricting the analysis to those patients who were currently receiving therapy directed at their hematological malignancy, albeit not statistically significant.
← all excerpts
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
1
—
—